Topoisomerase inhibitor - Wikipedia
Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII).
A Mini Review of Novel Topoisomerase II Inhibitors as Future ...
The large number of reports of topoisomerase II inhibitors in the recent literature reflect the high level of interest in topoisomerase II inhibitors as therapeutic targets. Several reports have confirmed the structural similarity between topo IIα and topo IIβ.
Targeting DNA topoisomerase II in cancer chemotherapy - Nature
2009年4月20日 · Onda, T. et al. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II...
Targeting DNA topoisomerase II in cancer chemotherapy - PMC
Drugs targeting topoisomerase II fall into two categories, Top2 poisons and Top2 catalytic inhibitors. Many Top2 poisons have demonstrated anti-cancer activity. Top2 poisons can be further sub-divided into intercalating and non-intercalating poisons.
Prospects of Topoisomerase Inhibitors as Promising Anti ...
Topoisomerase I inhibitors, which include irinotecan and topotecan, are agents that interact with the DNA-topoisomerase I complex and avert resealing of the DNA. The accretion of DNA breaks leads to the inhibition of DNA replication and cell death.
Dual Inhibitors of Human DNA Topoisomerase II and Other ...
2019年10月8日 · Human topoisomerase II (topo II) is a type II topoisomerase that has been shown to be an effective target in the treatment of a wide spectrum of cancers. It is targeted by the anticancer drugs etoposide, doxorubicin, daunorubicin, and mitoxantrone ( 1–4 , …
Topoisomerase II inhibitors design: Early studies and new ...
This thematic review summarizes the recent advances in the anticancer activity of the most potent topoisomerase II inhibitors (anthracyclines, epipodophyllotoxins and fluoroquinolones) their modes of action, and structure-activity relationships (SARs) organized chronologically in the last ten years from 2013 to 2023.